Gliomas (grade I-III), Other sarcoma diseases, Bone sarcomas
Other clinical trials
The analysis of the binding specificity of the newly developed tracer is carried out ex vivo on tumor tissue from patients with chondrosarcoma and gliomas and investigates whether the mIDH inhibitor AG-120 labeled with 18F is suitable for the specific visualization of the mutated enzyme in tissue sections. Testing on tissues with different IDH mutations allows the assessment of the binding specificity depending on the respective IDH mutation. The results allow an evaluation of the potential suitability of [18F]AG-120 for non-invasive diagnostics for the localization of an mIDH-positive tumor and potential recurrences/metastases in the patient.
The analysis of the binding specificity of the newly developed tracer is carried out ex vivo on tumor tissue from patients with chondrosarcoma and gliomas and investigates whether the mIDH inhibitor AG-120 labeled with 18F is suitable for the specific visualization of the mutated enzyme in tissue sections. Testing on tissues with different IDH mutations allows the assessment of the binding specificity depending on the respective IDH mutation. The results allow an evaluation of the potential suitability of [18F]AG-120 for non-invasive diagnostics for the localization of an mIDH-positive tumor and potential recurrences/metastases in the patient.
